Phase Forward to Host Seminars on Driving Efficiencies in Trial Supply Management

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it will host free seminars on “Driving Efficiencies in Trial Supply Management,” to discuss the benefits of using integrated interactive response technology (IRT) for trial supply management activities.

The seminars will take place from 9:45 a.m. to 1:15 p.m. local time at the following dates and locations:

Tuesday, October 13 – Radisson SAS Scandinavia Hotel, Copenhagen, Denmark
Wednesday, October 14 – Le Méridien Montparnasse, Paris, France
Thursday, October 15 – Radisson BLU Hotel, Zurich Airport, Switzerland
Friday, October 16 – The White House, Old Windsor, U.K.

During the seminars, members of the Phase Forward interactive response technology team including Jagath Wanninayake, vice president; An Pollenus, associate director, IRT project management; and Johan Verboven, manager, IRT project management, will discuss the importance of the latest developments in IRT enabling global trial management processes to be further streamlined, as well as best practices for project management and global support.

Additionally, the team will address the benefits of integrating the company’s IRT solution with InForm™ GTM, the company’s market leading electronic data capture (EDC) system. Customer case studies will also be presented by representatives from Bayer, CS² Clinical Supplies Consulting Services and Servier to demonstrate how the IRT solution can be leveraged to more effectively manage the drug supply process.

To register and to view the full agenda, visit the Phase Forward Web site.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the effectiveness and market acceptance of Phase Forward’s technologies and services, the benefits that may be realized by customers using Phase Forward’s technologies and services, and the ability of Phase Forward to persuade customers and prospective customers of these benefits. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, a lack of market acceptance of new and existing technologies such as those offered by Phase Forward, changes in customers’ opinions of and experiences with these technologies and services, and the ability of Phase Forward to convince current and potential customers to order its new technologies and services, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward’s public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024